A spokesperson for Mesothelioma Explained shares the latest information on mesothelioma research.

HOUSTON, TX, July 25, 2017 /24-7PressRelease/ — He states, “We are pleased to announce the addition of our new comprehensive website content featuring important updates about mesothelioma, mesothelioma symptoms and mesothelioma causes.

“Additionally, we have also added new content to our occupations pages and treatment pages that explain the occupational factors contributing to the development of mesothelioma along with the most available and effective treatment options. To cite an example from our occupations pages, once you click on the page, you will see an extensive number of occu[ations. Once you find an occupation that might be meaningful to you, simply click on the occupation and you will find a detailed overview about how a specific type of work can contribute to the development of mesothelioma.”

Recognizing Mesothelioma Symptoms

With the mesothelioma variables, symptoms may be related to the cancer location as well as the stage of the cancer. Some patients may experience a fluid buildup, while others may develop a tumor. The prognosis for each individual patient may be related to the patient’s symptoms. If you, or a loved one are experiencing any of the symptoms listed below, please schedule a doctor’s appointment as soon as possible.

Symptoms Related to the Type of Mesothelioma

Pleural Mesothelioma

– Pain in the chest
– A buildup of fluid
– Trouble breathing
– Continual coughing

Peritoneal Mesothelioma

– Stomach pain
– Fluid Buildup
– Losing weight
– Trouble eating, or trouble with feeling hungry

The type of mesothelioma and the stage of development a patient is in are two major factors in any type of treatment. The current types of mesothelioma treatment used includes chemotherapy, surgery, and radiation as well as some new clinical options that might be available.

WT1 Vaccine FDA Approval Expected as a Second-Line Mesothelioma Treatment

There are positive indications about additional medical help for mesothelioma patients who may soon benefit from the first second-line treatment for the disease. Once the FDA approves the WT1 vaccine, a large percentage of patines could benefit. Almost all mesothelioma patients express the WT1 antigen. As a result, this new vaccine would allow a majority of patients to potentially benefit from the WT1 vaccine.

The most current research shows that the WT1 cancer vaccine is especially effective as an enhancement to existing mesothelioma treatments. The vaccine benefits are described as a second-line treatment for malignant pleural mesothelioma capable of preventing a recurrence after the use of first-line therapy such as surgery, chemotherapy, and/or radiation.

Reports indicate that a phase III clinical trial should be in place this summer to build on the success rate of a recent phase II trial. Fortunately, due to the drug’s phase II success rate, the U.S. Food and Drug Administration cleared the way for the approval of the vaccine with an orphan drug designation.

With orphan drugs the medical community and patients have access to the availability of safe and efficacious products for use in the treatment of rare diseases. There are benefits for drug sponsors with the ‘orphan’ status which allows the drug sponsor to take advantage of incentives for the development of these products until the marketing approval stage.

The following measures apply to all stages of the drug’s development:

– Research: tax credits for clinical research;
– Expanded information of the required application file for marketing approval: this process requires technical involvement during the expansion file process along with an easy to understand administrative procedures (reduction of the time required for a waiting period and a reduction of the amount of registration fees);

Marketing: exclusivity of seven years is granted after the marketing approval process.

Sellas Life Sciences Group, the biopharmaceutical company developing the vaccine, released a statement from Dr. Andres Gutierrez, chief medical officer who stated that the company does not want to over promise vaccine results. That being said, he believes that the development of the vaccine is moving in the right direction.

About Mesothelioma Explained

Our primary goal at Mesothelioma Explained is to provide and explain as much information as possible to both patients and their loved ones diagnosed with mesothelioma. We offer our site as a guide and reliable resource to help explain every option and support resource that is available to you.

Our Pledge to Our Visitors

“Mesothelioma Explained will always provide accurate and current information.”

Inquiries
Media Contact: Astria Davenport
Phone: (281) 612-7397
Email: info@karstvonoiste.com
Consumer Contact: Astria Davenport
Phone: (281) 612-7397
Email: info@karstvonoiste.com
19500 State Highway 249, Suite 420
Houston, TX 77070
We hope you have found this information helpful. Please contact us with any questions.


For the original version of this press release, please visit 24-7PressRelease.com here